Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb 12:105:adv41325.
doi: 10.2340/actadv.v105.41325.

Patient Preferences and Cosmetic Outcomes Following Destructive Treatments for Non-facial Basal Cell Carcinoma: A Mixed Methods Study

Eva Backman  1 , Birgit Heckemann  2 , Martin Gillstedt  3 , Sam Polesie  3 , John Paoli  3
Affiliations
Randomized Controlled Trial

Patient Preferences and Cosmetic Outcomes Following Destructive Treatments for Non-facial Basal Cell Carcinoma: A Mixed Methods Study

Eva Backman et al. Acta Derm Venereol. .

Abstract

The high prevalence of basal cell carcinoma (BCC) entails a substantial burden on healthcare systems. Interest in non-surgical treatment methods for low-risk BCCs, including destructive treatments, is increasing. Dermatologists often highlight suboptimal cosmetic outcomes as drawbacks of destructive treatments, also for non-facial lesions. Patient perspectives regarding scarring and cosmetic outcomes in relation to other relevant factors are largely unknown, yet important to consider in shared decision-making when choosing treatment. This study investigates patient perceptions of scarring following destructive treatments and explores important factors in treatment decisions for non-facial BCCs. Through a mixed-methods design, cosmetic outcomes, patient satisfaction, scarring concerns, and treatment preferences were evaluated within an ongoing randomized clinical trial on destructive treatments for low-risk BCCs. Overall, 157 patients with 425 non-facial scars were assessed. Most patients were not concerned about scar appearance, highlighting a discrepancy compared with dermatologists' general concerns regarding inferior cosmetic outcome. Instead, when opting for specific treatments, patients listed clearance rates as the most important factor, followed by convenience and time consumption. We believe the results are important both in the context of patient-centred care and in "choosing wisely" when deciding between BCC treatments.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Overview of the randomized controlled trial with performed procedures/evaluations. Cur: curettage; cryo: cryosurgery; ED: electrodesiccation; FU: follow-up visit; nBCC: BCC with nodular features; sBCC: superficial BCC; vs: versus.
Fig. 2
Fig. 2
(A) Patient satisfaction with the scars and (B) patient concerns about the scars (mean and 95% confidence interval), stratified by sex and age groups. Lower scores indicate a more positive evaluation of the scars.
Fig. 3
Fig. 3
Patients’ ranking of factors of importance when choosing treatment methods for basal cell carcinoma. 1, most important; 2, second most important; 3, third most important; 4, least important.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–1080. 10.1111/j.1365-2133.2012.10830.x - DOI - PubMed
    1. Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. . Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol 2019; 80: 303–317. 10.1016/j.jaad.2018.03.060 - DOI - PubMed
    1. Rogers HW, Coldiron BM. Analysis of skin cancer treatment and costs in the United States Medicare population, 1996–2008. Dermatol Surg 2013; 39: 35–42. 10.1111/dsu.12024 - DOI - PubMed
    1. Eriksson T TG. Samhällskostnader för hudcancer 2011. Swedish radiation safety authority. Rapportnummer: 2014:49. ISSN: 2000-0456. Available from: www.stralsakerhetsmyndigheten.se
    1. Noels E, Hollestein L, Luijkx K, Louwman M, de Uyl-de Groot C, van den Bos R, et al. . Increasing costs of skin cancer due to increasing incidence and introduction of pharmaceuticals, 2007–2017. Acta Derm Venereol 2020; 100: adv00147. 10.2340/00015555-3463 - DOI - PMC - PubMed

Publication types

Grants and funding

Funding sources The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-728261).

LinkOut - more resources